TY  - GEN
AU  - Bliuc,D
AU  - Tran,T
AU  - van Geel,T
AU  - Adachi,J D
AU  - Berger,C
AU  - van den Bergh,J
AU  - Eisman,J A
AU  - Geusens,P
AU  - Goltzman,D
AU  - Hanley,D A
AU  - Josse,R G
AU  - Kaiser,S
AU  - Kovacs,C S
AU  - Langsetmo,L
AU  - Prior,J C
AU  - Nguyen,T V
AU  - Center,J R
TI  - Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study
SN  - 1433-2965
PY  - 2019///1212
KW  - Aged
KW  - Alendronate
KW  - therapeutic use
KW  - Bone Density Conservation Agents
KW  - Canada
KW  - epidemiology
KW  - Diphosphonates
KW  - Etidronic Acid
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Osteoporosis
KW  - drug therapy
KW  - Osteoporotic Fractures
KW  - mortality
KW  - Prospective Studies
KW  - Risedronic Acid
KW  - Risk Factors
KW  - Risk Reduction Behavior
N1  - Publication Type: Journal Article; Multicenter Study; Observational Study
UR  - https://doi.org/10.1007/s00198-018-4806-0
ER  -